A focused 2026 clinical landscape deep dive into NCT07675668, evaluating QG101-23-0 in Hypertrophic Cardiomyopathy: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.

A focused 2026 clinical landscape deep dive into NCT06830629, evaluating MZE-829 in APOL1-Mediated Kidney Disease: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.

A focused 2026 clinical landscape deep dive into NCT07211685, evaluating BAY-3401016 in Alport Syndrome: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.

A focused 2026 clinical landscape deep dive into NCT06824987, evaluating Opemalirsen in APOL1-Mediated Kidney Disease: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.

A focused 2026 clinical landscape deep dive into NCT07654140, evaluating SAL-0140 in Resistant Hypertension: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.

Summit Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Nuvation Bio 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Kura Oncology 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

AbCellera Biologics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Xencor 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

MacroGenics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Zymeworks 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.